It’s been getting frantic out there lately for sellers in the healthcare industry. In our market research, we’re increasingly hearing a common message: Payers and TPAs are not closing enough deals with employers fast enough. Providers and Integrated Delivery Systems are not closing enough deals with payers or direct to employers fast enough to sustain
Industry transition to value-based care & reimbursement (VBC/R) is happening. In fact, it’s happening faster than many comfortably predicted just 24 months ago. But in our work helping providers and payers plan and begin implementing various VBC/R strategies over the last 18 months, we have encountered a significant amount of confusion and misunderstanding around some
Specialty drug management programs are complex by nature with disparate multiple stakeholders. Increasing availability and cost of specialty drugs create an unsustainable financial burden for payers. How do you most effectively integrate and manage the many detailed program components, organizations, and tactics? Combining your core strategies that you previously implemented from our Combat Specialty Drug
I recently had the privilege of speaking at the 2015 AMIA Policy Invitational in Washington, DC. The theme of this year’s event was how policymakers can impact the on-going evolution of Electronic Health Records (EHRs). What a great group of people! Read more to get my top 5 takeaways from the event. 1. Health Information
In our last post we looked at four key threats to payers from industry devolution with value based reimbursement. These included: Administrative Service Disintermediation Network Management Disintermediation Health Management Disintermediation Loss of Negotiating Leverage Each threat is largely a result of the consolidation of provider organizations of all types into multi-modal comprehensive integrated delivery systems.